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Abstract: Review on CXCR1, with data on DNA/RNA, on the protein encoded and where the gene is implicated. 
 
Identity 
Other names: C-C, C-C-CKR-1, CD128, CD181, 
CDw128a, CKR-1, CMKAR1, IL8R1, IL8RA, 
IL8RBA 
HGNC (Hugo): CXCR1 
Location: 2q35 
Local order: Orientation: minus strand. 
Note 
CXCR1 together with IL8RB, another high affinity IL-
8 receptor, and its pseudogene (IL8RBP), form a gene 




The CXCR1 gene (il8ra) is 4149 bp long and is 
composed of two exons, one of them included in the 
coding region (1053 bp) CXCR1 has 165 known SNPs; 
many of them correlate with disease states.  
Genetic locus: CXCR1, together with its homolog 
CXCR2 (76% amino acids identity) and its pseudogene 
(il8rp), reside in chromosome 2q34-35. The high 
homology and close chromosomal localization between 
the three genes suggest gene duplications. 
Transcription 
Transcripts: primer extension analysis revealed two 
start sites for CXCR1 (Sprenger et al., 1995). In 
addition, neutrophils contain two transcripts of CXCR1 
(2.0 and 4.0 kb) which result from the usage of 
alternative poly adenylation signals.  
Transcription regulators: PU.1, which belongs to the ets 
family of transcription factors, is a major activator of 
CXCR1 expression (Wilkinson and Navarro, 1999).  
HIF1 and NF-kappaB mediate the transcription of 
CXCR1 under hypoxia in prostate cancer cells 
(Maxwell et al., 2007).  
CXCR1 mRNA expression is also regulated by G-CSF 
(Lloyd et al., 1995). 
Pseudogene 
Conservation during evolution: the CXCR1 gene was 
present in the common ancestor of chordates and has 
orthologs in diverse species, from lizards and Xenopus 
to primates.  
There is a high level of homology between CXCR1 
from human, rabbit, rat, and mouse. The sequencing of 
the coding region of CXCR1 in worldwide human 
populations and 5 representative nonhuman primate 
species revealed accelerated protein evolution in the 
human lineage, mainly at the N-terminal 
ligand/receptor recognition domain (Liu et al., 2005). 












350 amino acids, 39791 Da. 
CXCR1 is a G protein coupled receptor (GPCR), 
composed of seven transmembrane (TM) helices, an N-
terminal ligand binding domain and a signaling 
cytoplasmic tail. 
Expression 
Expression in tissues: according to SAGE (serial 
analysis of gene expression), CXCR1 is mainly 
expressed in the bone marrow, retina, heart, lungs and 
in the placenta. 
Expression in cell types: CXCR1 is expressed on a 
wide variety of cell types, including neutrophils, 
monocytes, CD8 T cells, mast cells, basophils, natural 
killer cells, keratinocytes, fibroblasts, neurons, 
endothelial cells, and melanocytes. 
Expression regulators: CXCR1 was found to be up-
regulated by IL6, by a yet-unknown mechanism 
(Eikawa et al., 2010). 
Localisation 
CXCR1 resides in the plasma membrane and 
transduces signals into the cell (figure 1). 
Function 
Upon binding to its ligands, CXCR1 transduces signals 
via the phosphatidylinositol-calcium second messenger 
system and plays an important role in acute 
inflammation. IL-8 (CXCL8), the main ligand of 
CXCR1, is a powerful neutrophil chemotactic factor 
and its binding to CXCR1 induces activation and 
migration of neutrophils (Holmes et al., 1991; Liu et 
al., 2005).  
In neutrophils, receptor activation also stimulates the 
release of granule enzymes and the generation of 
superoxide in respiratory burst (Jones et al., 1996).  
In addition to its effect on immune cells, CXCR1 may 
be important in regulating vasculogenesis and 
consequent tumor growth (Strieter et al., 1995).  
The signaling pathway of CXCR1 as a G protein 
coupled receptor is presented in figure 1. Noteworthy, 
CXCR1 signaling also activates monomeric, low 
molecular weight G proteins of the Ras and Rho 
families (Laudanna et al., 1996). 
Ligand selectivity: CXCR1 displays a relatively narrow 
selectivity and high preference for IL-8. At low affinity 




Highly expressed by melanoma cells and and mediates 
their proliferation and invasiveness in vitro and tumor 
growth in mice experiments (Singh et al., 2009). 
Recently, it was shown as a potential target for T cell 
engineering, a finding which highly impacts on 
adoptive cell immune-therapy for melanoma patients 
(Sapoznik et al., 2012). 
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Breast cancer 
Note 
CXCR1 is over-expressed in tumor and cascular 
endothelial cells, as shown by immunohistochemistry 
studies on a cohort of 50 breast cancer patients 
performed by Miller et al. (Miller et al., 1998). 
Recently, Singh and his colleagues showed that 
CXCR1 as well as CXCR2 are important mediators of 
breast cancer stem-like cells activity.  
Furthermore, blockade of CXCR1 and CXCR2 adds to 
the inhibitory effect of HER2-targeted therapy on these 
cells and may potentially serve as a novel therapeutic 
strategy for breast cancer (Singh et al., 2013). 
Colorectal cancer 
Note 
CXCR1 is over-expressed in colorectal cancer cells 
(Abolhassani et al., 2008) and antagonists of CXCR1 
and CXCR2 inhibit liver metastases of human colon 
cancer in a murine model (Varney et al., 2011).  
Interestingly, based on two large cohorts of population 
incident studies, Bondurant and his colleagues were 
recently able to show that SNPs in genes connected 
with the IL8 pathway (including CXCR1 and CXCR2) 
are associated with higher risk of both colon and rectal 
cancers (Bondurant et al., 2013). 
Prostate cancer 
Note 
CXCR1 is over-expressed in tumor cells from human 
prostate biopsies (Murphy et al., 2005). Depletion of 
CXCR1 by RNA interference in androgen-independent 
human prostate cancer cells induces cell death and 
reduced proliferation in vitro (Shamaladevi et al., 
2009).  
In consistence with that, down- regulation of CXCR1 
by shRNA or by a specific antagonist lead to inhibition 
of human xenograft growth in immune-deficient mice 
(Shamaladevi et al., 2009; Liu et al., 2012). 
Nasopharyngeal carcinoma 
Note 
Immune-histochemical analysis of 30 patients with 
nasopharyngeal carcinoma proved that its expression in 
tumor tissue significantly correlates with a shorter 
overall survival rate.  
Thus it is an indicator of poor prognosis in 
nasopharyngeal carcinoma (Horikawa et al., 2005). 
Chronic obstractive pulmonary disease 
(COPD) 
Note 
CXCR1 polymorphisms are identified polymorphisms 
associated with COPD and asthma, as shown by 
Stemmler et al. by screening 50 COPD patients 
(Stemmler et al., 2005).  
Pignatti and colleagues found that neutrophilic asthma 
patients have similar expression levels of CXCR1 as 
COPD patients and that CXCR1 expression is 
negatively correlated with the inflammatory infiltrate in 
the airways (Pignatti et al., 2005). 
Urinary tract infection recurrent 
Note 
CXCR1 was first identified as a candidate gene for 
urinary tract infections when Godaly et al showed that 
mIL-8Rh mutant mice developed acute pyelonephiritis 
with severe renal scattering (Godaly et al., 2001).  
Lundstedt et al. have afterwards identified two 
sequence variants which were shown to impair 
transcription of CXCR1 and led to reduced levels of the 
CXCR1 protein in children prone to urinary tract 
infections (Lundstedt et al., 2007). 
Psoriasis 
Note 
A single study by Arenberger et al showed in a small 
cohort of psoriasis patients that CXCR1 is slightly 
though significantly over-expressed in 
polymorphonuclear leukocyte infiltration in the 
epidermis as compared to normal volunteers 
(Arenberger et al., 1992). 
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